CMMB Chemomab: Company Short-Term Debts

Public company logo of Chemomab Therapeutics (CMMB)

The short-term debt trend chart maintained by GURU.Markets analysts demonstrates the impact of logistical risks and patent disputes, with the parameter stabilizing at 0.00. Highly qualified scientists from Israel and the US ensure stability. Liver fibrosis therapy trials are creating positive momentum, while investors have already priced current R&D costs into Chemomab Therapeutics (CMMB) quotes.

CMMB (Chemomab Therapeutics) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

Metric breakdowns and analytics for Chemomab Therapeutics Ltd (CMMB)

- stock price and consensus target price:
Stock Price Chemomab|CMMB - Consensus Target
- company stock capitalization data:
Market Capitalization Chemomab Therapeutics Ltd.|CMMB - Company Buyout Price
- business book valuation details:
Book Value per Share Chemomab Therapeutics|CMMB - Book Capitalization|Market Value to Book Value Ratio chemomab.com|CMMB - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Chemomab Therapeutics|CMMB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Chemomab|CMMB - Company Aggregate Indebtedness|Debts to Book Capitalization Chemomab Therapeutics Ltd.|CMMB - Long-Term Debt|Company Short-Term Debts Chemomab Therapeutics|Quick Liquidity Indicator chemomab.com
- net income and valuation multiples indicators:
CMMB - Final Profit
Summary company analysis:chemomab.com (CMMB)
Manufactured products of Chemomab Therapeutics

For the biotech startup Chemomab Therapeutics (CMMB), which focuses on clinical trials for fibrotic pathologies, liquidity control is critical when deploying venture capital. An analysis of short-term liabilities allows for an assessment of total obligations maturing within one year, reflecting the ability of the Israeli management to effectively balance operating expenses and debt load to maintain the issuer's solvency.

Main competitors

Vertex - Company Short-Term Debts|Alnylam Pharmaceuticals, Inc. (ALNY) - Company Current Liabilities|INSM: Company Short-Term Debts|UTHR - Short-Term Debt Volume|BMRN (BioMarin Pharmaceutical) - Company Short-Term Debts|Company Short-Term Debts bridgebio.com|Company Short-Term Debt BGM Group Ltd (BGM)|Company Short-Term Debt COGT (Cogent Biosciences Inc)|Company Short-Term Debts XERS (Xeris Biopharma Inc)|Short-Term Debt Volume Keros Corp (KROS)|ARCT: Company Current Liabilities|Current Liabilities ETON|KMDA: Company Short-Term Debts|Short-Term Debt Fulcrum Therapeutics Inc (FULC)|ABEO (Abeona Therapeutics, Inc.) - Company Short-Term Debts|Company Short-Term Indebtedness MREO (Mereo BioPharma Group PLC)|Company Current Liabilities PLX (Protalix BioTherapeutics)|PLRX (pliantrx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Applied Therapeutics APLT|RNTX (Rein Therapeutics Inc.) - Current Liabilities|Gelteq Limited Inc - Company Short-Term Debts|Company Short-Term Loans and Borrowings AYTU (Aytu BioPharma, Inc.)|SRXH: Company Short-Term Debts|Polyrizon (PLRZ) - Company Short-Term Debts|Company Short-Term Debt Aeterna Zentaris Inc|CYTH: Company Short-Term Loans and Borrowings|Company Short-Term Debt Inozyme Pharma, Inc. (INZY)|Company Current Liabilities Reneo Pharmaceuticals, Inc RPHM|Company Short-Term Debts CSCI (COSCIENS Biopharma Inc.)